Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy.
about
A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive conditionMelanoma: oncogenic drivers and the immune systemIdentification of potential small molecule binding pockets on Rho family GTPasesA novel role of farnesylation in targeting a mitotic checkpoint protein, human Spindly, to kinetochoresSynthesis, structure and assessment of the cytotoxic properties of 2,5-dimethylazaferrocenyl phosphonates.A small molecule inhibitor of isoprenylcysteine carboxymethyltransferase induces autophagic cell death in PC3 prostate cancer cells.Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitorsTargeting protein prenylation for cancer therapyA tagging-via-substrate approach to detect the farnesylated proteome using two-dimensional electrophoresis coupled with Western blottingA phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.Isoprenoids, small GTPases and Alzheimer's disease.Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice.Protein isoprenylation regulates osteogenic differentiation of mesenchymal stem cells: effect of alendronate, and farnesyl and geranylgeranyl transferase inhibitors.Evaluation of alkyne-modified isoprenoids as chemical reporters of protein prenylation.Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.A defect in protein farnesylation suppresses a loss of Schizosaccharomyces pombe tsc2+, a homolog of the human gene predisposing to tuberous sclerosis complex.Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy.Cancer cells differentially activate and thrive on de novo lipid synthesis pathways in a low-lipid environment.Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.The role of nuclear lamin B1 in cell proliferation and senescence.Poly(ADP-ribose) polymerase-13 and RNA regulation in immunity and cancer.Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group.Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activationHeme oxygenase is not involved in the anti-proliferative effects of statins on pancreatic cancer cells.A Farnesyltransferase Acts to Inhibit Ectopic Neurite Formation in C. elegans.Genetic and biochemical alterations in non-small cell lung cancer.Developing innovative strategies for advanced transitional cell carcinoma of the bladder.Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cellsA highly sensitive prenylation assay reveals in vivo effects of bisphosphonate drug on the Rab prenylome of macrophages outside the skeleton.Alteration of protein prenylation promotes spermatogonial differentiation and exhausts spermatogonial stem cells in newborn micePhase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignanciesmiR-22 inhibits tumor growth and metastasis by targeting ATP citrate lyase: evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer.Recent advances in chemical proteomics: exploring the post-translational proteome.Polyisoprenylated methylated protein methyl esterase overexpression and hyperactivity promotes lung cancer progression.Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.Targeted therapy in the treatment of malignant gliomasMetabolism strikes back: metabolic flux regulates cell signaling.The analytical determination of isoprenoid intermediates from the mevalonate pathway.Lonafarnib for cancer and progeria.Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring.
P2860
Q24655745-7A7052C4-B6E3-4D02-8B12-A352F0008D31Q26775598-3189D812-6D0D-4B94-A2FA-1CB003CF0402Q28481320-F2D0A36D-7497-43E9-B7D5-9F6A222F0799Q30635394-4B0215FE-3FA4-4F8F-AF67-058559A83F90Q31029121-888BB181-59FC-48B6-81AF-8A3382AD6812Q33330582-BB570EA0-71C7-46A2-8830-B80631CCAB3AQ33669995-FFF0CF95-1C4A-4702-B4FA-3E7C159E3A0AQ33679239-48DF1193-63BD-4ED6-A0F8-234A1622527EQ33812895-2BCBDA55-4CF5-4237-A567-431260806D06Q33914284-07EEC76D-9923-4EB4-B347-71E794914D7BQ33915441-B28C182F-5EC0-48F4-8326-7C6A154ACE34Q34181861-716A0BF7-39E5-45C3-99F4-BB1C2708DE10Q34636254-5CDC688C-6938-4BF6-BDD4-3FDFA53A73B3Q34679579-7DA85D18-C5AE-4D2B-9946-0E0CBA0F0326Q34758477-5B2CB3A1-C34D-4A23-8DEA-9D749E6890C3Q34894950-EA28673F-E859-487A-9510-0E1E6717D176Q34940620-59F320D2-8DCE-40BF-A428-4082836D1F1CQ35249792-69592520-A661-4D17-8512-D32BD96B9835Q35525569-A44BDDDD-3002-440B-98CA-9A3A85BC7F1CQ35642054-BF2B09AE-249A-42D3-BDD1-ED851B9AB3CBQ35691217-E186428C-82C1-43A0-B990-A2B6005144BCQ35729250-E67A3AF2-76AE-443F-9143-164B6FB0699EQ35828643-5F197F0D-4AFA-4F2A-BC66-325AD7EB1C81Q36016816-3060652F-B396-49B7-B8E1-53B9357BA625Q36051770-A8EEDA0E-250E-41C3-93CF-2ADD1B3EB672Q36184584-CEF4EE65-665D-4D92-BFA5-F83ADAD7F4A2Q36352085-5DCD3993-1605-4DB7-AA2E-DA8D38289665Q36868759-80A4E73D-1E79-47FD-BABB-556E74D89694Q36997869-4E6FFD69-321D-4912-880A-4D548966D928Q37061610-817FD47B-7D7F-444A-AFDE-CB99FF1BCC81Q37441525-86B201E1-1E63-4273-BA22-9A60ECCA4E67Q37536852-3DEC9D3A-EE19-4C77-9360-6620BCE63CDFQ37537095-D408CC5C-15E8-4F41-B0D8-0E779802CF0EQ37650129-D9A798BA-A6FB-4630-92B4-F1FE1782F545Q37699439-D1F393C3-1873-41E6-AF62-2DA8BCE20DD0Q37771247-C04CA976-5E42-4E05-89C5-363249F641ECQ37821147-DDB74230-7912-43F9-8638-3CF75FA845E6Q37905648-90829E28-7651-46B0-A2FC-E7B1B7C342A9Q38012480-CC89667D-E04C-44E4-9685-A9FB2670BA8FQ38091649-CFD17ED4-E6C8-4401-A7AD-63387DDDC8C6
P2860
Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Protein farnesylation: implica ...... formation, and cancer therapy.
@ast
Protein farnesylation: implica ...... formation, and cancer therapy.
@en
Protein farnesylation: implica ...... formation, and cancer therapy.
@nl
type
label
Protein farnesylation: implica ...... formation, and cancer therapy.
@ast
Protein farnesylation: implica ...... formation, and cancer therapy.
@en
Protein farnesylation: implica ...... formation, and cancer therapy.
@nl
prefLabel
Protein farnesylation: implica ...... formation, and cancer therapy.
@ast
Protein farnesylation: implica ...... formation, and cancer therapy.
@en
Protein farnesylation: implica ...... formation, and cancer therapy.
@nl
P1433
P1476
Protein farnesylation: implica ...... formation, and cancer therapy.
@en
P2093
Saïd M Sebti
P304
P356
10.1016/J.CCR.2005.04.005
P577
2005-04-01T00:00:00Z